Neurocrine Biosciences Inc - ESG Rating & Company Profile powered by AI
Alternative companies in the rating peer group for Neurocrine Biosciences Inc are displayed. This report of Neurocrine Biosciences Inc incorporates data from across the web and also from available disclosures by Neurocrine Biosciences Inc. Scroll down to the bottom of the page for potential risks for Neurocrine Biosciences Inc based on sector, geography and size.
Neurocrine Biosciences Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 1.3, social score of 6.9 and governance score of 5.3.
4.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 852 | Vaccibody AS | 4.6 | High |
| 852 | argenx SE | 4.6 | High |
| 868 | Neurocrine Biosciences Inc | 4.5 | High |
| 868 | CARsgen Therapeutics Holdings Ltd | 4.5 | High |
| 868 | Boiron SA | 4.5 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Neurocrine Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Neurocrine Biosciences Inc report the average age of the workforce?
Sign up for free to unlockDoes Neurocrine Biosciences Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Neurocrine Biosciences Inc offer flexible work?
Sign up for free to unlockDoes Neurocrine Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Neurocrine Biosciences Inc conduct supply chain audits?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Neurocrine Biosciences Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose water use targets?
Sign up for free to unlockDoes Neurocrine Biosciences Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Neurocrine Biosciences Inc have a product recall in the last two years?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Neurocrine Biosciences Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Neurocrine Biosciences Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose parental leave metrics?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Neurocrine Biosciences Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Neurocrine Biosciences Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Neurocrine Biosciences Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose its waste policy?
Sign up for free to unlockDoes Neurocrine Biosciences Inc report according to TCFD requirements?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose energy use targets?
Sign up for free to unlockDoes Neurocrine Biosciences Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Neurocrine Biosciences Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Neurocrine Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.